ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis

G
eneva, Switzerland and Boston, MA - November 7, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today reported completion of patient recruitment of its Phase 2b EDELWEISS clinical trial of OBE2109, its oral gonadotropin releasing hormone (GnRH) receptor antagonist, for the treatment of pain associated with endometriosis.

"The completion of patient recruitment in our Phase2b EDELWEISS clinical trial is a testament to our clinical research and operations teams, and underscores ObsEva's commitment to bringing new treatment alternatives to women suffering from debilitating diseases such as endometriosis," said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva.

Approximately 330 patients are expected to be randomized in the EDELWEISS clinical trial, and primary endpoint efficacy results continue to be anticipated in mid-2018.